^
HER-2 expression
|
Endometrial Adenocarcinoma
|
HER-2 expression
|
Endometrial Adenocarcinoma
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Endometrial Adenocarcinoma
|
HER-2 overexpression
|
Endometrial Adenocarcinoma
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
Endometrial Adenocarcinoma
|
HER-2 positive
|
Endometrial Adenocarcinoma
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Endometrial Adenocarcinoma
|
MSI-H/dMMR
|
Endometrial Adenocarcinoma
|
AZD1775 Sensitive: C3 – Early Trials
|
AZD1775 Sensitive: C3 – Early Trials
|
HER-2 positive
|
Endometrial Adenocarcinoma
|
HER-2 positive
|
Endometrial Adenocarcinoma
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
ER positive
|
Endometrial Adenocarcinoma
|
ER positive
|
Endometrial Adenocarcinoma
|
letrozole + zoledronic acid Sensitive: C4 – Case Studies
|
letrozole + zoledronic acid Sensitive: C4 – Case Studies
|
MSH6 F1088fs
|
Endometrial Adenocarcinoma
|
MSH6 F1088fs
|
Endometrial Adenocarcinoma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
HER-2 amplification
|
Endometrial Adenocarcinoma
|
HER-2 amplification
|
Endometrial Adenocarcinoma
|
lapatinib Sensitive: D – Preclinical
|
lapatinib Sensitive: D – Preclinical
|
HER-2 amplification
|
Endometrial Adenocarcinoma
|
HER-2 amplification
|
Endometrial Adenocarcinoma
|
trastuzumab + lapatinib Sensitive: D – Preclinical
|
trastuzumab + lapatinib Sensitive: D – Preclinical
|
HER-2 amplification
|
Endometrial Adenocarcinoma
|
HER-2 amplification
|
Endometrial Adenocarcinoma
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
